Katya Ravid is a Biochemistry and Cell Biology professor at Boston University Chobanian & Avedisian School of Medicine.
[3] Alongside her title of the inaugural incumbent of the Barbara E. Corkey Professor, she also became the founding director of the Evans Center for Interdisciplinary Biomedical Research in 2009.
Launched in 2015, the office seeks to foster and support different biomedical research programs in collaboration with faculty and other members of Boston University's medical center and the Charles River campuses (such as the Clinical Translational Science Institute).
She is the co-director of a lab focused on cancer-associated thromboembolism as affected by health disparities in collaboration with the American Heart Association.
In 2021, Boston University's newspaper, The Brink, wrote about her research findings on the linkage between black cancer patients and their higher susceptibility to blood clots.
In 2021, The American Association for the Advancement of Science's newsletter, EurekaAlert!, credited Dr. Ravid for her research and discovery of two drugs, PXS-LOX_1 and PXS-LOX_2, which can slow down the development of bone marrow cancer called primary myelofibrosis (PMF).